Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

34 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of human HT1080 fibrosarcoma cells treated with cytostatic drugs

ABSTRACT: HT1080 fibrosarcoma cells were treated with cytostatic drugs and analysed on Affymetrix microarray to identify genes and pathways regulated by these compounds. The array images were processed using Affymetrix MAS 5.0 software. and normalized by global scaling or scaled to a polyA+ spike mask

ORGANISM(S): Homo sapiens

SUBMITTER: Ludger Klein-Hitpass

PROVIDER: E-GEOD-2238 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways.

Lehnhardt Marcus M Klein-Hitpass Ludger L Kuhnen Cornelius C Homann Heinz Herbert HH Daigeler Adrien A Steinau Hans Ulrich HU Roehrs Sonja S Schnoor Laura L Steinstraesser Lars L Mueller Oliver O

BMC cancer 20050707

<h4>Background</h4>Because of the high resistance rate of fibrosarcomas against cytotoxic agents clinical chemotherapy of these tumors is not established. A better understanding of the diverse modes of tumor cell death following cytotoxic therapies will provide a molecular basis for new chemotherapeutic strategies. In this study we elucidated the response of a fibrosarcoma cell line to clinically used cytostatic agents on the level of gene expression.<h4>Methods</h4>HT1080 fibrosarcoma cells wer ...[more]

PMID: 16001973

Similar Datasets

Targets of cytostatic drugs in HT1080 fibrosarcoma

Project description:HT1080 fibrosarcoma cells were treated with cytostatic drugs and analysed on Affymetrix microarray to identify genes and pathways regulated by these compounds. The array images were processed using Affymetrix MAS 5.0 software. and normalized by global scaling or scaled to a polyA+ spike mask Keywords = Cytostatic drugs Keywords = Actinomycin D Keywords = Doxorubicin Keywords = Vincristine Keywords = apoptosis Keywords: ordered

2006-02-04 | GSE2238 | GEO

TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mafosfamide in human fibrosarcoma cells.

Project description:Microarray analysis revealed differential gene expression patterns of HT1080 cells treated with various chemical compounds alone and in combination (trabectedin, doxorubicin, mafosfamide, TRAIL, taurolidine) Microarray analysis of HT1080 cells treated with various chemical compounds alone and in combination (trabectedin, doxorubicin, mafosfamide, TRAIL, taurolidine)

2011-09-30 | E-GEOD-32441 | biostudies-arrayexpress

Transcriptomic profiling of HT1080 fibrosarcoma cells of mesenchymal or amoeboid migratory phenotype

Project description:Amoeboid and mesenchymal migration of cancer cells both contribute to metastatic spreading of tumors. To characterize gene expression profiles underlying the different migratory modes, we performed RNA sequencing of HT1080 fibrosarcoma cells undergoing mesenchymal-amoeboid transition induced by either doxycycline-inducible constitutively active RhoA or dasatinib treatment. Cells were kept in three-dimensional collagen gels with or without induction for 48 hours. RNA was isolated with a modified Chomczynski protocol. RNA-seq libraries were constructed from DNase I treated, rRNA depleted total RNA and sequenced with Illumina 2000/2500 sequencers.

2019-07-29 | E-MTAB-6823 | biostudies-arrayexpress

Expression data from RECK-overexpressing HT1080 fibrosarcoma cells

Project description:RECK, a glycosylphosphatidylinositol-anchored glycoprotein, inhibits the enzymatic activities of some matrix metalloproteinases (MMP), thereby suppressing tumor cell metastasis; however, the detailed mechanism is still obscure. In this study, we compared the gene expression profiles between mock- and RECK-transfected HT1080 cells. Three established cell lines were selected for RNA extraction and hybridization on Affymetrix microarrays: (1) mock-transfected HT1080 cells, designated as HT1080-Zeo, (2) RECK-overexpressing HT1080 cells, designated as HT1080-RECK, and (3) RECK/4NQ-overexpressing HT1080 cells (in which four N-glycosylation asparagine residues of RECK (Asn86, Asn200, Asn297, and Asn352) were replaced with glutamine residues), designated as HT1080-RECK/4NQ.

2010-04-14 | E-GEOD-21306 | biostudies-arrayexpress

Expression analysis of human CRABP1 gene and R131A CRABP1 mutant in HT1080 cells

Project description:Investigation of whole genome gene expression level changes in HT1080 fibrosarcoma cell line after transfection CRABP1 gene and R131A CRABP1 mutant (arginine-alanine substitution in a protein active site, protein lacks the ability to interact with retinoic acid), compared to HT1080 line transfected with empty pLXSN vector. A twelve samples on one chip study using total RNA recovered from four separate cultures of HT1080 human fibrosarcoma cell line transfected with empty pLXSN vector, four HT1080 cell line cultures transfected with CRABP1 gene and four HT1080 cell line cultures transfected with R131A CRABP1 mutant. Each sample on a chip measures the expression level of 44,049 genes from human genome with three-fold technical redundancy.

2013-09-01 | E-GEOD-48673 | biostudies-arrayexpress

Effect of CDK8/19 inhibitor Senexin A on p21-regulated gene expression in human HT1080 p21-9 cells with IPTG-inducible p21

Project description:p21 (CDKN1A) expression from an IPTG-inducible promoter in HT1080 p21-9 cells was previously shown to inhibit a set of genes, many of which are involved in cell cycle progression, and to upregulate another set of genes, some of which have been implicated in cancer and age-related diseases. We have now developed Senexin A, a small-molecule inhibitor of p21-induced transcription, which we found to be a selective inhibitor of CDK8 and CDK19. Here we tested the effect of Senexin A on the induction and inhibition of transcription by p21. In this dataset, we include microarray gene expression data from samples of HT1080 p21-9 cells that were either untreated, treated with p21-inducing IPTG alone, with Senexin A alone, or with IPTG and Senexin A. This experiment shows that Senexin A inhibits primarily the induction but not the inhibition of gene expression by p21. The data for each of the four samples were normalized to the sample from untreated cells, using GeneSpring GX. Fold changes in gene expression upon the addition of IPTG with or without Senexin A were compared using Microsft Excel. Changes in the expression of specific GO categories of genes were compared using GeneSpring.

2012-08-12 | E-GEOD-39464 | biostudies-arrayexpress

Genome binding profile of TFIIH helicases XPB and XPD in HT1080 cells

Project description:The conserved TFIIH helicases XPB and XPD play key roles in transcription initiation and DNA repair. To investigate the functions of these helicases on a genome-wide scale, we performed ChIP-seq of endogenous XPB and XPD in the HT1080 human fibrosarcoma cell line. 2 ChIP samples and 1 unenriched input control from the same crosslinked chromatin pool

2014-02-18 | E-GEOD-44849 | biostudies-arrayexpress

BMP1/Tolloid-like substrates by iTRAQ degradomics

Project description:In this study, we used an iTRAQ-based quantitative proteomic approach to reveal the release of proteolytic fragments from the cell surface or the ECM by BMP-1. Thirty-seven extracellular proteins were found in significantly higher or lower amounts in the conditioned medium of HT1080 cells overexpressing BMP-1 and thus, could be considered as candidate substrates. Strikingly, three of these new candidates (betaglycan, CD109 and neuropilin-1) were TGF-Beta co-receptors, also acting as antagonists when released from the cell surface, and were chosen for further substrate validation.

2014-09-29 | PXD000786 | Pride

Proteomic profiling of HT1080 fibrosarcoma cells of mesenchymal or amoeboid migratory phenotype

Project description:Amoeboid and mesenchymal migration of cancer cells both contribute to metastatic spreading of tumors. To characterize proteome changes underlying the different migratory modes, we performed mass spectrometry profiling of HT1080 fibrosarcoma cells undergoing mesenchymal-amoeboid transition induced by either doxycycline-inducible constitutively active RhoA or dasatinib treatment. Cells were kept in three-dimensional collagen gels with or without induction for 48 hours, lysed and processed for mass spectrometry analysis. In case of the inducible RhoA system, we also performed parallel two-dimensional experiments with cells on top of a dense layer of collagen (it was not feasible with dasatinib treatment).

2020-04-23 | PXD010425 | Pride

Homo sapiens

Project description:Targets of cytostatic drugs in HT1080 fibrosarcoma

| PRJNA91501 | ENA